Urogen Pharma’s (URGN) Buy Rating Reiterated at D. Boral Capital

by · The Cerbat Gem

D. Boral Capital restated their buy rating on shares of Urogen Pharma (NASDAQ:URGN – Free Report) in a report released on Monday,Benzinga reports. The brokerage currently has a $33.00 price target on the stock.

Other analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Urogen Pharma in a research report on Monday, October 27th. Wall Street Zen upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Urogen Pharma currently has an average rating of “Moderate Buy” and a consensus price target of $33.00.

Check Out Our Latest Stock Analysis on URGN

Urogen Pharma Stock Performance

NASDAQ URGN opened at $23.14 on Monday. Urogen Pharma has a one year low of $3.42 and a one year high of $30.00. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -6.69 and a beta of 1.29. The company’s 50-day simple moving average is $23.65 and its two-hundred day simple moving average is $19.71.

Urogen Pharma (NASDAQ:URGN – Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.03. The business had revenue of $27.48 million during the quarter, compared to analysts’ expectations of $34.09 million. Equities analysts expect that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $25.00, for a total transaction of $250,000.00. Following the sale, the insider owned 139,025 shares of the company’s stock, valued at approximately $3,475,625. The trade was a 6.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Urogen Pharma

Several institutional investors and hedge funds have recently made changes to their positions in the stock. CWM LLC boosted its holdings in Urogen Pharma by 18.0% during the third quarter. CWM LLC now owns 4,271 shares of the company’s stock worth $85,000 after buying an additional 650 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Urogen Pharma by 9.4% in the second quarter. China Universal Asset Management Co. Ltd. now owns 9,261 shares of the company’s stock worth $127,000 after acquiring an additional 797 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Urogen Pharma by 7.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after acquiring an additional 1,653 shares in the last quarter. Main Street Financial Solutions LLC grew its position in shares of Urogen Pharma by 8.2% during the 2nd quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock valued at $356,000 after acquiring an additional 1,968 shares during the period. Finally, Osaic Holdings Inc. increased its stake in shares of Urogen Pharma by 491.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after purchasing an additional 3,070 shares in the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Urogen Pharma Company Profile

(Get Free Report)

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.

Recommended Stories